A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing The Efficacy, Safety And Tolerability Of Three Doses Of Orally Administered Bms-986368, A Faah/Mgll Inhibitor, For The Treatment Of Spasticity In Participants W
Posted Date: Apr 30, 2025
- Investigator: Shahla Hosseini
- Specialties: Multiple Sclerosis, Neurology, Neuromuscular Disorders
- Type of Study: Drug
This study is assessing the safety, efficacy, and tolerability of an FAAH/MAGL Inhibitor through the observation of three doses to treat spasticity symptoms in those with Multiple Sclerosis. This study has a short duration with participant engagement lasting up to 20 weeks in total, where 14 weeks is the minimum with an optional 6 week extension period offered. Participants will have visits on a weekly basis, where majority are in person with some telephone visits scheduled every few weeks instead.
Criteria:
Participants Must Be Between The Ages Of 18 To 70 Years Old, Have A Diagnosis Of Ms, A History Of Spasticity For At Least 6 Months, An Edss Score Between 3.0-6.5, And Is Willing To Undergo A Washout Period Of Current Medications Taken For Treatment Of Spasticity. Additional Inclusion/Exclusion Criteria Review Will Need Completed Prior To Enrollment In The Study.
Keywords:
Multiple Sclerosis, Spasticity, Faah/Magl Inhibitor
For More Information:
Kristine Suder
NULL
suderkl@ucmail.uc.edu